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C A N C E R
Redox-responsive nanoplatform for codelivery of  
miR-519c and gemcitabine for pancreatic  
cancer therapy
Xiaofei Xin1, Virender Kumar1, Feng Lin1, Vinod Kumar1, Rajan Bhattarai1, Vijaya R. Bhatt2, 
Chalet Tan3*, Ram I. Mahato1*
Desmoplastic and hypoxic pancreatic cancer microenvironment induces aberrant expression of miRNAs and 
hypoxia-inducible factor-1 (HIF-1) responsible for gemcitabine (GEM) resistance. We demonstrated that miR-519c 
was down-regulated in pancreatic cancer and transfection of miR-519c in GEM-resistant pancreatic cancer cells 
inhibited HIF-1 level under hypoxia. We synthesized redox-sensitive mPEG-co-P(Asp)-g-DC-g-S-S-GEM polymer, 
with GEM payload of 14% (w/w) and 90% GEM release upon incubation with l-glutathione. We synthesized mPEG-
co-P(Asp)-g-TEPA-g-DC for complex formation with miRNA. Chemical modification of miR-519c with 2′-O-methyl 
phosphorothioate (OMe-PS) at 3′ end enhanced its stability and activity without being immunogenic. Epidermal 
growth factor receptor targeting peptide GE11 decoration increased tumor accumulation of micelles after sys-
temic administration and significantly inhibited orthotopic desmoplastic pancreatic cancer growth in NSG mice 
by down-regulating HIF-1 and genes responsible for glucose uptake and cancer cell metabolism. Our multifunc-
tional nanomedicine of GEM and OMe-PS–miR-519c offers a novel therapeutic strategy to treat desmoplasia and 
hypoxia-induced chemoresistance in pancreatic cancer.
INTRODUCTION
Pancreatic cancer is one of the most chemotherapy-resistant can-
cers and a leading cause of cancer-related mortality with a dismal 
5-year survival rate of 8 to 10% (https://seer.cancer.gov/statfacts/
html/pancreas.html). Gemcitabine (GEM) is a first-line therapy for 
pancreatic cancer either alone or in combination with other drugs 
such as nanoparticle albumin-bound paclitaxel or nab-paclitaxel (1). 
However, the clinical effect of single-agent GEM is modest due to 
its rapid metabolism, inefficient delivery to the desmoplastic tumor, 
and development of chemoresistance (2, 3). The combination therapy 
of GEM and nab-paclitaxel versus GEM alone increases survival 
along with an increase in grade 3 neutropenia, fatigue, and neuro-
pathy (4). The use of FOLFIRINOX (5-fluorouracil, oxaliplatin, 
irinotecan, and leucovorin combination), as compared to GEM, 
significantly prolongs survival but at the expense of higher grade 3 
or 4 toxicities (5).
Most patients with pancreatic cancer are present with metastatic 
or inoperable disease, and therefore, systemic polychemotherapy 
remains the treatment of choice. The median survival of patients 
with metastatic pancreatic cancer is still less than a year with either 
FOLFIRINOX or GEM and nab-paclitaxel (6, 7). Therefore, safer 
and more effective combination of GEM and novel drugs further 
need to be developed particularly for older or less fit patients or 
those with significant comorbidities, who cannot tolerate intensive 
chemotherapy.
Chemotherapy resistance in pancreatic cancer involves multiple 
mechanisms. GEM-resistant cells mainly represent cancer stem cells 
and epithelial-to-mesenchymal transformation (EMT) phenotype 
(8, 9). Desmoplasia produces hypoxic microenvironment, stimulat-
ing hypoxia-inducible factor-1 (HIF-1), which, in turn, modulates 
tumor metabolism, induces profibrotic and angiogenic responses, and 
mediates the overexpression of adenosine triphosphate–binding 
cassette superfamily G member 2 (ABCG2). As a member of the 
ABC transporter superfamily, ABCG2 functions as a drug efflux 
pump and has been reported to play a role in GEM resistance in 
pancreatic cancer (10, 11). Because of an increase in high-glucose 
metabolism in GEM-resistant cells, the flux of glycolytic intermedi-
ates is directed toward nonoxidative pentose phosphate pathway 
(PPP), leading to an increase in pyrimidine biosynthesis and pool of 
deoxycytidine triphosphate (dCTP). The structural similarity be-
tween dCTP and GEM, a nucleoside analog, results in a molecular 
competition to bind the replicating DNA, reducing the efficacy of 
GEM. Hypoxia is responsible for an increase in sonic hedgehog (SHH) 
signaling and smoothened (SMO) expression in pancreatic cancer and 
activation of the transcription factor glioma-associated oncogene (GLI) 
(12). These changes result in further generation of fibrosis and a decrease 
in blood flow, creating a desmoplasia-hypoxia vicious cycle.
MicroRNAs (miRNAs) regulate gene expression by the degra-
dation of target mRNAs, repressing of mRNA translation, or up- 
regulating of target genes. Aberrant expressions of miRNAs correlate 
with altered expression of genes responsible for stemness, metastasis, 
tumor metabolism, hypoxia, and chemoresistance (13). We previously 
reported differential down-regulation of miR-205 and miR-let7b in 
human pancreatic cancer tissues and cells (14). Further, we demon-
strated that the combination of GEM-conjugated polymeric micelles 
and miR-205 significantly inhibited pancreatic tumor growth in 
mice after systemic administration, as miR-205 sensitized resistant 
pancreatic cells to GEM (8, 15). miR-519c is of particular interest in 
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pancreatic cancer, as it is down-regulated in pancreatic cancer, binds 
to HIF-1 mRNA, and can inhibit HIF-1 expression, leading to 
sensitization of pancreatic cancer cells (16, 17). We hypothesize that 
a combination of GEM and miR-519c can target HIF-1 and ABCG2, 
resensitize resistant pancreatic cancer cells to GEM, and result in 
decreased desmoplasia. Moreover, 2′-O-methyl phosphorothioate 
(2′-OMe-PS) modification of RNA based on our previous study 
(18) was applied to miR-519c to increase its stability, binding affinity, 
and functional potential and decrease immunostimulatory properties.
Nanoparticulate delivery systems have shown distinct advantages 
in increasing drug accumulation at the tumor site after systemic 
administration. GEM delivery is limited by its poor pharmacokinetic 
profiles and dense desmoplasia, which may be overcome by a 
GEM-conjugated delivery system. We recently developed methoxy 
poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene 
carbonate)-graft-gemcitabine-graft-dodecanol (mPEG-b-PCC-g-GEM-
g-DC), which conjugates GEM via stable amide bonds and self-assembles 
into micelles, with 12% (w/w) GEM loading and 2.5-fold higher 
GEM accumulation in orthotopic pancreatic cancer compared to 
free GEM (2). Redox-sensitive polymeric micelles are very promis-
ing due to their controlled drug release inside the tumor cells in the 
presence of intracellular stimuli, including glutathione (GSH) (19). 
GSH concentration in tumor cells is several times higher than that 
in the extracellular microenvironment and normal tissues (20). Epi-
dermal growth factor receptor (EGFR) has been overexpressed in 40 
to 80% of pancreatic cancers. Cells that overexpress EGFR will accu-
mulate the functionalized particles, resulting in greater cytotoxicity. 
We hypothesized that EGFR targeted GE11 peptide mixed micelles 
system based on tetraethylene pentamine (TEPA) for complex 
formation with miRNA and GSH-sensitive polypeptide for GEM con-
jugation via disulfide bond for targeted delivery of GEM and OMe-
PS–miR-519c will result in a synergistic inhibition of pancreatic cancer 
without excess toxicity. Our in vitro and in vivo studies confirmed 
that mixed OMe-PS–miR-519c–complexed and GEM-conjugated 
mixed micelles effectively inhibit pancreatic tumor growth.
RESULTS
Overexpression of HIF-1 in patient pancreatic cancer 
tissues and cell lines
We first established a GEM-resistant pancreatic ductal adenocarci-
noma (PDAC) cell model by incubating wild-type MIA PaCa-2 cells 
with increasing concentrations of GEM over 2 months. The result-
ing GEM-resistant MIA PaCa-2R cells were 25-fold more resistant 
compared to the wild-type MIA PaCa-2 cells, as reflected by the 
pronounced increase in the median inhibitory concentration value 
from 2 to 50 M. Our immunohistochemical analysis demonstrated 
a high expression of HIF-1 protein in patient-derived pancreatic 
cancer tissues but a negligible expression in adjacent healthy patient 
tissues (fig. S1A). Western blot analysis of MIA PaCa-2R cells 
demonstrated that the expression level of HIF-1 was very low 
under normoxic conditions but significantly increased, reaching 
the highest level at 4 hours after incubation of MIA PaCa-2R cells 
under hypoxic condition (fig. S1B).
miR-519c inhibits HIF-1, Hh signaling, and tumor  
cell invasion
miR-519c was significantly down-regulated in pancreatic cancer 
tissue compared to adjacent normal tissues, as determined by real- 
time reverse transcription polymerase chain reaction (RT-PCR) 
(Fig. 1A). Similarly, we observed a significantly low miR-519c ex-
pression level in pancreatic cancer cell lines such as HPAF-II, 
Capan-1, and MIA PaCa-2R, compared to nonmalignant pancreatic 
cells HPDE (human pancreatic duct epithelial) (Fig. 1B). With target 
prediction by miRTarBase, we confirmed that miR-519c directly 
targets HIF-1 and ABCG2, indicating its potential utility to reverse 
hypoxia-induced chemoresistance.
Expression of SHH, SMO, and GLI1 was significantly higher under 
hypoxic versus normoxic conditions, as determined by Western blot 
analysis. Transfection of pancreatic cancer cells with Lipofectamine/
miR-519c complexes significantly inhibited the expression of HIF-
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Fig. 1. miR-519c expression is down-regulated in pancreatic cancer, and its overexpression inhibits HIF-1, Hh signaling, and cell migration under hypoxic 
condition. miR-519c was down-regulated in patient tissues (A) and pancreatic cancer cell lines (B), compared to paired normal tissues and normal pancreatic cells such 
as HPDE. Further, miR-519c inhibited the expression of HIF-1 and Hh ligands such as SHH, SMO, and GLI1 after the transfection of MIA PaCa-2R cells with Lipofectamine/
miR-519c under hypoxic condition (C and D). (E) miR-519c also inhibited cell migration under hypoxic condition when MIA PaCa-2R cells were cultured on Transwell 
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We observed that addition of human pancreatic stellate cells (hPSCs)– 
conditioned medium to MIA PaCa-2R cells induced tumor cell in-
vasion, especially under hypoxic condition (Fig. 1E), indicating that the 
exposure of MIA PaCa-2R cells to desmoplastic microenvironment 
enhances their invasion capacity. Additional treatment of MIA PaCa- 
2R cells with miR-519c inhibited cell migration under hypoxic con-
dition and desmoplasia (Fig. 1E).
miR-519c inhibits glucose influx and metabolism  
under hypoxia
Flow cytometry data demonstrated an up-regulation of glucose 
transporter 1 (GLUT1) expression in MIA PaCa-2R cells under 
hypoxic conditions. Transfection of these cells with miR-519c, but 
not scrambled miRNA, significantly inhibited GLUT1 expression 
under hypoxic conditions (Fig. 2A and fig. S2). As a glucose analog, 
the uptake of 2-deoxyglucose (2-DG) by MIA PaCa-2R cells was 
significantly increased under hypoxic conditions even when these 
cells were transfected with scrambled miRNA. This is expected, as 
GLUT1 is a well-known HIF-1 target. Transfection of these cells with 
miR-519c resulted in a significant decrease in 2-DG uptake under 
hypoxic conditions (Fig. 2B), suggesting that miR-519c negates 
hypoxia-induced elevation in glucose uptake, using 2-DG as a GLUT1 
substrate. The concentration of dCTP was significantly higher under 
hypoxic conditions but declined following the transfection of MIA 
PaCa-2R cells with Lipofectamine/miR-519c complexes (Fig. 2C), 
indicating that the intracellular level of dCTP is severely suppressed 
by miR-519c. Hypoxia is known to increase glycolytic influx and 
pyrimidine biosynthesis in tumor cells. The mRNA expression lev-
els of several known targets of HIF-1 were up-regulated under the 
hypoxic condition. These targets included NME/NM23 nucleoside 
diphosphate kinase (NME4) involved in PPP and nucleotide bio-
synthesis pathways, as well as lactate dehydrogenase (LDH), hexo-
kinase 2 (HKII), and transketolase (TKT) involved in glucose 
metabolism. The expression level of these targets genes was signifi-
cantly inhibited after the transfection of MIA PaCa-2R cells with 
miR-519c but not by scrambled miRNA (Fig. 2D). Together, these 
results provide strong evidence that miR-519c repletion attenuates 
glucose metabolism and reduces intracellular dCTP pool.
miR-519c sensitizes hypoxic GEM-resistant tumor cells 
to cell killing by GEM
Because of an increase in high-glucose metabolism in GEM-resistant 
cells, the flux of glycolytic intermediates is directed toward nono-
xidative PPP, leading to an increase in pyrimidine biosynthesis and 
pool of dCTP. As GEM is a nucleoside analog, its efficacy is affected 
by both nucleoside synthesis and their cellular uptake. The presence 
of dC resulted in a dose-dependent decrease in cytotoxicity after 
treatment with GEM (Fig. 3A), suggesting that treatment with dCTP 
increased GEM resistance in MIA PaCa-2R cells. The combination 
of miR-519c and GEM demonstrated a dose-dependent synergistic 
effect on cell killing. In contrast, treatment with scrambled miRNA 
had little effect on cell killing (Fig. 3B). Apoptosis assay further con-
firmed these observations (fig. S3A). The effect of miR-519c on cell 
cycle of MIA PaCa-2R cells was determined by flow cytometry after 
the transfection of MIA PaCa-2R cells with miR-519c under normoxic 
and hypoxic conditions. Treatment with miR-519c compared to 
scrambled miRNA under hypoxic conditions resulted in a signifi-
cant increase in the percentage of cells in the G2 phase (Fig. 3C and 
fig. S3A). These data suggest that miR-519c inhibited pancreatic 
cancer cell proliferation by inducing G2 phase cell cycle arrest.
The Western blot analysis demonstrated that drug resistance–
related protein ABCG2 and transcription factor c-MYC (which 
promotes cancer cell proliferation) and programmed death-ligand 









































































































   





Fig. 2. miR-519c inhibits glucose metabolism to inhibit GEM resistance to pancreatic cancer cells under hypoxic condition. (A and B) miR-519c inhibited 2-DG uptake, as 
well as expression of GLUT1 and dCTP, but not scrambled miRNA under hypoxic condition after transfection of MIA PaCa-2R cells with Lipofectamine miR-519c. Cells transfected 
with Lipofectamine/scrambled miRNA complexes were used as the control. (C) miR-519c decreased dCTP level under hypoxic condition. (D) In addition, miR-519c but not scram-
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indicated that the hypoxic-dependent up-regulation of ABCG2- and 
c-MYC–magnified GEM resistance and PD-L1 can promote immune 
escape of tumor cells from cytotoxic T lymphocytes and contribute 
to the immunosuppression in tumors under hypoxia. Then, the 
apoptosis rate was investigated by the coculturing of MIA PaCa-2R 
and peripheral blood lymphocytes with or without miR-519c treat-
ment under normoxic and hypoxic conditions (fig. S4). We observed 
a significant increase in apoptosis of MIA PaCa-2R cells in the co-
culture system with miR-519c transfection under hypoxia. Treatment 
of MIA PaCa-2R cells with miR-519c but not scrambled miRNA in-
hibited expression of ABCG2, c-MYC, and PD-L1 (Fig. 3, D and E). 
These data suggest that miR-519c has the potential to improve the 
cytotoxicity of activated T cells and immunotherapy.
Three-dimensional (3D) desmoplastic tumor spheroids were de-
veloped to mimic the hypoxic microenvironment in pancreatic cancer 
by mixing and culturing hPSCs and MIA PaCa-2R cells in hanging 
drop plates. Live and dead assay was carried out after treatment with 
miR-519c and GEM for 48 hours by confocal laser scanning micros-
copy. Fluorescein isothiocyanate–labeled calcein and propidium 
iodide binding to nucleic acids presented live and dead cells, respec-
tively. Treatment with the combination of miR-519c and GEM for 
9 days exhibited a significantly higher inhibition of tumor growth, 
leading to the collapse of tumor spheroids. In contrast, treatment 
with miR-519c or GEM alone failed to destroy tumor spheroids 
(Fig. 3F). These results suggest that miR-519c facilitates the resensi-
tization of pancreatic cancer cells to GEM.
Chemical modification with OMe-PS increases the stability 
and targeting efficiency of miR-519c without eliciting 
proinflammatory response
Chemical modifications can protect miRNA against nuclease deg-
radation and affect their nonspecific interaction with plasma proteins 
and cell membrane components. Therefore, modification of its 3′ 
end with OMe-PS stabilized miR-519c, which in good agreement 
with our previous study (18). We determined the effect of nucleases 
on miRNA stability by incubating unmodified miR-519c and OMe-
PS–miR-519c in 50% fetal bovine serum (FBS). miR-519c was 
degraded within an hour in 50% FBS at 37°C. When three-terminal 
nucleotides at the 3′ end of miR-519c guide strand were modified, 
with 2′-OMe-PS, its stability was substantially increased, resulting 
in significant levels of intact miRNA remained even after 24 hours 
of incubation at 37°C (Fig. 4A). Further, there was no loss of activity 
in cell killing due to this chemical modification. Incubation of MIA 
PaCa-2R cells with the combination of 100 nM OMe-PS–miR-519c 
or miR-519c and increasing concentrations of GEM demonstrated 
a dose-dependent synergistic effect on cell killing, with OMe-PS–
miR-519c being more potent than miR-519c (Fig. 4B).
To examine whether the chemical modification of miR-519c 
induces proinflammatory cytokine production, we determined the 
levels of interleukin-2 (IL-2) and IL-4 after incubating OMe-PS–
miR-519c and unmodified miR-519c with human peripheral blood 
mononuclear cells (hPBMCs) for 24 hours and measured cytokines 
released in hPBMC cultures using a cytokine multianalyte ELISArray 
kit. The antigen standard cocktail was added to the plate as the pos-
itive control. There was a little induction of cytokines due to miRNA 
treatment. Compared to miR-519c–treated groups, OMe-PS–miR-
519c–treated hPBMCs showed the lower release of cytokines, in-
cluding IL-2 and IL-4 (Fig. 4, C and D).
Argonaute 2 (AGO2) protein is a ribonuclease (RNase) and is an 
essential component of the RNA-induced silencing complex (RISC) 
where one strand of the mature miRNA duplex is first loaded onto 
AGO2 protein. AGO2-bound miRNA interacts with complementary 
regions of target mRNA and leads to either AGO2-mediated endo-
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Fig. 3. miR-519c and GEM synergistically inhibit pancreatic cancer cell proliferation and promote apoptosis. (A) Coincubation of GEM with 100 M dC-reduced 
drug potency. (B) Significant decrease in cell viability when MIA PaCa-2R cells were transfected with a combination of GEM and miR-519c under the hypoxic condition for 
48 hours, but GEM combination with scrambled miRNA was less effective. (C) miR-519c inhibited viability by arresting cell cycle in the G2-M phase. (D and E) miR-519c 
inhibits ABCG2, c-Myc, and programmed death-ligand 1 (PD-L1) expressions, which are up-regulated under hypoxic condition, but scrambled miRNA had little effect. 
(F) Combination of miR-519c and GEM was more effective in apoptotic cell death of tumor spheroids generated using MIA PaCa-R cells than either of them alone. The 
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efficiency. Therefore, we assessed the effect of chemical modifica-
tion of miR-519c on its association with AGO2 compared to un-
modified miR-519c and OMe-PS–miR-519c in the cytoplasm. As 
shown in Fig. 4E, the transfection of MIA PaCa-2R with miR-519c 
and OMe-PS–miR-519c was resulting in 3- and 16-fold higher RISC 
loading than that of the control group. Consequently, higher RISC 
loading resulted in improved inhibition of HIF-1 and ABCG2 
(Fig. 4F). Notably, the AGO2 association did not differ between 
normoxic and hypoxic conditions.
Redox-sensitive nanocarriers achieve combined delivery 
of OMe-PS–miR-519c and GEM
On the basis of the results above, we selected OMe-PS–miR-519c 
over miR-519c for in vivo studies due to its higher stability, en-
hanced RISC loading, and affinity. We used our mPEG-co-P(Asp)-
g-TEPA-g-DC cationic copolymer for complex formation with 
miRNA and used for preparing mixed micelles with mPEG-co-
P(Asp)-g-Ala-SS-GEM-g-DC for codelivery of OMe-PS-miR-591c 
and GEM. 1H nuclear magnetic resonance (NMR) of mPEG-co-
P(Asp)-g-TEPA-g-DC and mPEG-co-P(Asp)-g-Ala-SS-GEM-g-DC 
is shown in Fig. 5 (A and B). The percentage of GEM loading in 
mPEG-co-P(Asp)-g-Ala-SS-GEM-g-DC was calculated to be 14% 
on the basis of the integration of peak at 3.5 parts per million (ppm) 
for the CH2 of mPEG (f) and peaks at 7.8 to 8.22, 7.09, 5.29 to 6.16, 
4.36, 4.27, 3.0, and 2.93 ppm (a, b, c, d, e, g, and h), respectively 
(protons on GEM-S-S-NH2). The rest of the carboxylic acid groups 
in the polymer were also reacted with dodecylamine (DC) to provide 
sufficient hydrophobicity for micelle formation, as indicated by the 
peaks at 0.85, 0.98, and 1.23 ppm (i, j, and k), respectively. In TEPA 
polymer, the broad peak at 2.98 ppm for TEPA and the characteristic 
peaks at 1.38, 1.24, and 0.85 ppm (e, f, and g) for DC chain suggest their 
successful conjugation (Fig. 5B). 1H NMR spectra of intermediate prod-
ucts, such as mPEG-PBLA (Poly--benzyl-L-aspartate) in dimethyl 
sulfoxide (DMSO)–d6, Boc-Ala-SS-OH in CDCl3, Diboc-GEM in 
DMSO-d6, Boc-Ala-SS-Diboc-GEM in CDCl3, Ala-SS-GEM in DMSO-d6, 
and GE11-PEG-co-P(Asp)-g-DC in DMSO-d6, are also shown in fig. S5.
The particle size distribution of miR-519c–complexed and GEM- 
conjugated redox-sensitive mixed micelles was prepared using mPEG-
co-P(Asp)-g-Ala-SS-GEM-g-DC and mPEG-b-PCC-g-DC-g-TEPA 
(Fig. 5C). As determined by atomic force microscopy, these mixed 
micelles were spherical in shape and narrow particle size distribu-
tion, with the mean particle size of 129.5 ± 5 nm (Fig. 5D). GEM 
loading was 14% in the polymer conjugate, as determined after 
alkaline hydrolysis and analysis with high-performance liquid 
chromatography–ultraviolet (HPLC-UV), which was consistent with 
the NMR calculation. Micelles prepared using mPEG-co-P(Asp)-g-
TEPA-g-DC had the mean particle size of 77.18 nm and formed a 
complex with miRNA at a very low N:P ratio (4:1) (fig. S6). The 
particle size of mixed micelles based on the above two polymers was 
160 nm. Drug-polymer conjugates and miRNA were analyzed for 
their drug release profiles at different conditions. In the absence of 
GSH, GEM conjugates were stable and released only up to 5% of 
GEM within 4 days. Disulfide conjugates released significant amounts 
of GEM within an hour in 10 mM GSH. These results confirmed 
that disulfide conjugates were stable at physiological conditions but 
rapidly released GEM in the reducing environment. The release 
profile demonstrated a controlled release of miRNA from GEM 
conjugates/TEPA micelles over 2 days (Fig. 5F).
EGFR-targeted nanocarriers effectively deliver GEM 
and OMe-PS–miR-519c to desmoplastic pancreatic tumor 
in an orthotopic mouse model
To optimize GE11 peptide concentration for enhanced EGFR receptor– 



























































































Fig. 4. Chemically modified OMe-PS–miR-519c was more stable and effective but a little immunogenic compared to unmodified miR-519c. (A) Synergistic effect of OMe-
PS–miR-519c and GEM on cell viability after transfection of MIA PaCa-2R cells with 100 M OMe-PS–miR-519c and increasing concentrations of GEM for 48 hours under hypoxic 
conditions. (B) Stability of OMe-PS–miR-519c and unmodified miR-519c in 50% FBS. (C and D) Effect of miR-519c and OMe-PS–miR-519c on proinflammatory cytokines interleu-
kin-2 (IL-2) and IL-4, as analyzed by enzyme-linked immunosorbent assay. (E) Association of OMe-PS–miR-519c with endogenous AGO2 protein. (F) HIF-1 and ABCG2 expression 
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the cellular uptake of micelles after incubation of MIA PaCa-2R 
cells with coumarin G6–loaded mixed micelles prepared at 10:90, 
20:80, and 30:70 ratios of GE11 peptide–decorated micelles and 
nontargeted micelles. There was an increase in cellular uptake with 
increasing GE11 peptide concentration, but the level of cellular 
uptake for the mixed micelles at 20:80 and 30:70 ratios was similar 
(fig. S7A). To avoid the effect of high GE11 peptide concentration 
on micellar stability and systemic toxicity, we did not formulate 
targeted micelles beyond 30:70 ratio. Preincubation of cells with 
excess of free GE11 peptide significantly reduced the cellular uptake 
of the mixed micelles, indicating that the uptake was receptor medi-
ated (fig. S7A). Then, we determined the biodistribution of GEM 
to the tumor at 6 and 24 hours after systemic administration of 
nontargeted and EGFR-targeted GE11-decorated GEM-conjugated 
OMe-PS–miR-519c mixed micelles into desmoplastic pancreatic 
tumor–bearing nonobese diabetic/severe combined immunodeficient– 
gamma null (NSG) mice at the doses of GEM (20 mg/kg) and miRNA 
(1 mg/kg). Desmoplastic orthotopic mouse model recapitulates 
hypoxic tumor microenvironment responsible for decreased drug 
delivery and chemoresistance in pancreatic cancer. At 6 and 24 hours 
after administration, GEM and miRNA were extracted from the tumor, 
and the liver and their concentrations were determined by liquid 
chromatography–tandem mass spectrometry (LC-MS/MS) (using 
5-Aza-2′-dC as an internal standard) and real-time PCR, respec-
tively. We observed significantly higher GEM and miR-519c con-
centrations in the tumor at 6 and 24 hours after administration of 
GE11 peptide–decorated combination mixed micelles compared to 
nontargeted combination mixed micelles (Fig. 6A). In contrast, 
GEM concentrations in the liver at 6 and 24 hours after administra-
tion of GE11 peptide–decorated combination mixed micelles were 
significantly lower than those of the mice injected with nontargeted 
combination mixed micelles (fig. S8A). The relative levels of miR-
519c were higher in the tumor at 6 and 24 hours after administration 
of GE11 peptide–decorated combination mixed micelles compared 
to nontargeted combination mixed micelles (fig. S8C).
Combination therapy of GEM and OMe-PS–miR-519c via 
EGFR-targeted nanocarriers exerts superior efficacy against 
orthotopic pancreatic tumor growth
Desmoplastic orthotopic mouse model recapitulates hypoxic tumor 
microenvironment responsible for decreased drug delivery and 
chemoresistance in pancreatic cancer. Micelles were injected intra-
venously three times a week for 2 weeks, and tumor growth was 
monitored by in vivo imaging system (IVIS) bioluminescence 
imaging. The rationale of doses and schedules of individual drugs 
were designed on the basis of previous studies (21). Notably, the 
combination therapy had lower doses of individual drug and 
miRNA. GEM micelles and OMe-PS–miR-519c micelles separately 
controlled tumor growth significantly more than saline or free GEM. 
Nontargeted combination micelles demonstrated synergy and had 
greater tumor growth inhibition than either GEM-conjugated 
micelles or OMe-PS–miR-519c–complexed micelles, reflecting the 
ability of OMe-PS–miR-519c to down-regulate HIF-1 and resen-
sitize pancreatic cancer to GEM. EGFR-targeted GE11 peptide–
decorated mixed micelles were even more effective than nontargeted 
mixed micelles in controlling tumor growth (Fig. 6B). The tumor 
weight was the lowest for GE11 peptide–decorated combination 
micelles–treated group compared to all treated groups (Fig. 6C). 
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Fig. 5. Conjugation of GEM to redox-sensitive polymer via disulfide bond demonstrates rapid GEM release in the presence of GSH but negligible GEM release 
in the absence of GSH at pH 7.4. (A and B) 1H NMR spectra of mPEG-co-P(Asp)-g-TEPA-g-DC and mPEG-co-P(Asp)-g-Ala-SS-GEM-g-DC. (C) Particle size distribution of 
redox-sensitive mixed micelles, as determined by dynamic light scattering. (D) Surface morphology and particle size distribution of mixed micelles determined by atomic 
force microscopy. (E) mPEG-co-P(Asp)-g-TEPA-g-DC forms complexes with miRNA at the N:P (TEPA:miRNA) ratio of 4:1 and above, as determined by gel electrophoresis. 
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Hematoxylin and eosin (H&E) staining of tumor tissues confirmed 
the extensive apoptotic and necrotic cells throughout the tumor in 
the control group and the inhibition of proliferation of tumor cells 
in the treated groups. Compared to the control and free GEM 
group, the tumor samples from GEM conjugated redox- sensitive 
micelles–treated group exhibited with limited metastatic cells (Fig. 6E). 
Coinjection of hPSCs with MIA PaCa-2R cells stimulated tumor 




















































































































Fig. 6. Biodistribution and antitumor efficacy of GEM-conjugated OMe-PS–miR-519c–complexed redox-sensitive micelles after systemic administration into orthotopic 
desmoplastic pancreatic tumor–bearing mice. (A) Biodistribution of GEM and OMe-PS–miR-519c at 6 and 24 hours after injection of nontargeted (NT) and GE11-targeted 
micelles following intravenous injection at GEM dose of 20 mg/kg and miR-519c dose of 1 mg/kg. GEM concentration was determined by LC-MS/MS using 5-Aza-2′-dC as an 
internal standard for GEM quantification. miR-519c concentration was determined by real-time PCR. (B) Bioluminescence images of tumors and isolated tumor images at the 
end of the experiment. (C) Tumor weight after treatment and (D) body weight. (E) Representative microscopic pictures of immunohistochemical staining for HIF-1, -SMA, 









Xin et al., Sci. Adv. 2020; 6 : eabd6764     11 November 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
8 of 14
–smooth muscle actin (-SMA) in the tumor of the saline-treated 
group (Fig. 6E). Treatment of the mice with GEM-conjugated redox- 
sensitive micelles or miR-519c–complexed micelles showed a sig-
nificantly less -SMA–positive fibrotic area (Fig. 6E). However, 
the mice treated with the combination therapy showed the least 
-SMA–positive staining in the tumor.
Ki-67 protein is an excellent marker for determining the cell 
proliferation. Ki-67 staining of tumor tissues confirmed the exten-
sive cell proliferation in the nontreated control group compared 
to the free GEM-treated group. Tumor tissues treated with GEM- 
conjugated redox-sensitive micelles–treated group showed a signifi-
cantly lower number of cells Ki-67–positive cells (Fig. 6E). Furthermore, 
cleaved caspase-3 staining of tumor tissues indicated the induction 
of significant apoptosis by treatment with GEM redox-sensitive 
micelles and miR-519c micelles–treated groups, compared to free 
GEM- and saline-treated group. GE11 peptide–decorated combination 
micelles–treated group showed the lowest Ki-67 and highest cleaved 
caspase-3 expression compared to all other treatment groups (Fig. 6E). 
In addition, we determined the systemic toxicity of GE11-decorated 
combination micelles–treated groups and saline-treated control group 
by histological analysis of the major organs. There were no notice-
able histological changes observed in the livers, spleens, kidneys, 
and hearts from the treatment groups (fig. S9), suggesting that the 
mice tolerated GE11 peptide–decorated combination micellar for-
mulation of GEM and miR-519c treatment well.
These findings indicated that EGFR-targeted micelles were able 
to deliver miR-519c and GEM to the tumor sites and release the 
antitumor agents via redox responsiveness, thus resulting in maxi-
mum synergy against pancreatic cancer without additional toxicities.
DISCUSSION
PDAC is a recalcitrant disease characterized by highly aggressive 
cancer cells, extensive desmoplastic reaction, and hypovasculariza-
tion. These unique features endow PDAC tumors with an array of 
resistance mechanisms against standard-of-care chemotherapy treat-
ments (22). It is, therefore, urgent to identify novel targets that can 
sensitize tumor cells. Desmoplastic and hypoxic pancreatic tumor 
microenvironments play multifaceted roles in inducing chemotherapy 
resistance, promoting distant metastasis, and serving as a barrier to 
drug delivery (23). Hypoxic microenvironment activates quiescent 
PSCs in extracellular matrix (ECM) by up-regulation of Hh signal-
ing ligands (Fig. 1D). Strong desmoplasia severely affects vascular 
function, resulting in hypovascularization of the tumor, which 
up-regulates HIF-1 expression (fig. S1). Therefore, a cycle of hy-
poxia and desmoplasia is amplifying each other. This cycle could be 
blocked by HIF-1 inhibition, which was found sufficient enough 
to impede Hh signaling (24).
Aberrant expression of miRNA correlates with altered expression 
of genes responsible for stemness, metastasis, cancer metabolism, 
hypoxia, and chemoresistance (25). The advantage of miRNAs lies 
in their ability to modulate multiple cellular pathways simultaneously, 
which are difficult to target by small molecules and therapeutic pro-
teins. miR-519c is down-regulated in pancreatic cancer patient tis-
sues and different cell lines (Fig. 1, A and B) but can target HIF-1 
and Hh ligands such as SHH and GLI, as determined by Western 
blotting (Fig. 1, C and D). Therefore, miR-519c could be a promis-
ing strategy in the inhibition of desmoplasia of pancreatic cancer 
and other hypoxia-related genes. The presence of miR-519c prevented 
migration of MIA PaCa-2R cells in the presence of hPSC-conditioned 
medium (Fig. 1E), indicative of miR-519c–mediated inhibition of 
tumor cell–stromal metabolic interactions. The tumor microenvi-
ronment promotes the interactions between cancer cells and their 
surrounding cancer-associated fibroblasts (CAFs; PSCs in this case). 
This feedback is reciprocal, and CAFs can both promote and impair 
cancer progression, while cancer cells promote PSC activation, pro-
liferation, migration, and ECM remodeling capability via the Hh 
pathway. Activated PSCs secrete numerous growth factors includ-
ing platelet-derived growth factor, transforming growth factor–, 
and inflammatory cytokines in the tumor (26). Many reports sug-
gest that HIF-1 induces migration in pancreatic cancer cells by 
regulating genes such as EMT regulators Snail, chemokine (C-X3-C 
motif) receptor 1 (CX3CR1), and glucose metabolism (27, 28). We 
have shown that inhibiting HIF-1 decreased several metabolism- 
related genes such as GLUT1, NME4, LDHA, HKII, and TKT (Fig. 2, 
A and D), thus providing the rationale for reduced migration of 
MIA PaCa-2R cells in the presence of miR-519c.
Resistance to chemotherapeutic drugs in pancreatic cancer could 
have many causes, such as intrinsic resistance mechanisms and des-
moplastic microenvironments that promotes cancer cell resistance 
by providing an environment that hampers drug delivery. HIF-1–
mediated metabolic alterations that facilitate GEM resistance in 
pancreatic cancer cells have been recently reported (29). GEM- 
resistant pancreatic cancer cells maintain a higher dC pool. Increased 
glucose metabolism fuels GEM resistance in pancreatic cancer cells, 
supporting de novo synthesis of dC through nonoxidative PPPs. 
Here, we show that GEM resistance in hypoxic pancreatic cancer 
cells can be reversed by miR-519c repletion. The coordinated tran-
scription induction of genes encoding glycolytic enzymes and py-
rimidine synthesis in response to hypoxia is mediated by HIF-1. 
Consistent with HIF-1 down-regulation by miR-519c, we found 
that miR-519c may counteract hypoxia-induced increase in glyco-
lytic influx and intracellular dCTP level (Figs. 2 and 3).
Hypoxia up-regulates glucose metabolism, angiogenesis, and drug- 
resistant genes (30). HIF-1 signaling transactivates a multitude of 
target genes that enhance glucose uptake, as determined by an in-
crease in 2-DG (Fig. 2B), glycolysis, and oxidative phosphorylation, 
thus facilitating cancer cell survival under oxygen- and glucose- 
deprived microenvironments. HIF-1 also results in an increase 
in pancreatic cancer, leading to increased dCTP pool and GEM re-
sistance (Figs. 2D and 3A). Hypoxia and overexpression of HIF-1 
ultimately promote induction of an invasive and treatment-resistant 
phenotype of pancreatic cancer.
We have reported previously that under in vitro conditions, GEM 
is highly effective in mediating toxicity against human pancreatic 
cancer cells. In contrast, orthotopic tumors in the pancreas were 
resistant to systemic therapy of GEM. Many factors affect GEM 
efficacy in vivo, including higher-rate metabolism, dose-limiting 
toxicity, competition with cellular dCTP pool, various efflux mecha-
nisms, and poor penetration into the bulk of the tumor.
ABCG2 is an efflux transporter that is often observed in drug- 
resistant cancer cells and contributes to a multidrug resistance 
phenotype. ABCG2 may help provide a survival advantage during 
conditions of hypoxia and allow cells to escape the toxic effects 
of chemotherapeutic drugs. HIF-1 binds to the hypoxia response 
element, and binding of latter to the ABCG2 promoter increases its 
transcription in pancreatic cancer cells (31). Our data suggest that 
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resistance. Over the decades, researchers faced the technical hurdles 
associated with bringing a therapeutic oligonucleotide product to 
market. A key hurdle includes getting small interfering RNA/miRNA 
molecules into the right cells in vivo. Delivery of miRNAs is difficult 
because they are relatively large, chemically unstable, immuno-
genic, and negatively charged molecules that do not cross the cell 
membrane (32). Previously, we have shown that rationally designed 
chemically modified miRNA could provide an excellent solution by 
increasing their stability and decreasing their immunogenicity (18). 
Here, we chemically modified miR-519c with OMe-PS at its 3′ end 
to enhance stability, in vivo half-life, and loading affinity into the 
RISC (Fig. 4).
The therapeutic efficacy of GEM depends on its delivery to the 
tumor site, activation by dC kinase to GEM monophosphate, and 
evading deactivation by cytidine deaminase. As discussed above in 
detail, desmoplasia makes it difficult for GEM to achieve adequate 
accumulation inside the tumor after systemic administration. Pre-
viously, we have shown that PEGylation prolongs the circulation 
of GEM-conjugated micelles and improves its overall therapeutic 
effect (14).
EGFR overexpression is observed in pancreatic cancer cells (33). 
EGFR-binding monoclonal antibody cetuximab (C225) blocks the 
binding of EGFR ligands to the receptor. Although cetuximab can exert 
an anticancer effect in patients expressing wild-type KRAS, pancreatic 
cancer that expresses mutated KRAS (Kirsten rat sarcoma) in 95% of cases 
is resistant to cetuximab therapy. EGFR expression is also high in 
distant metastatic pancreatic cancer (34), hence provides an ideal 
candidate for targeted drug delivery. Previously, we demonstrated 
higher tumor accumulation when cetuximab-conjugated micelles were 
administered into orthotopic PC (pancreatic cancer)–bearing NSG mice, 
which resulted in low tumor burden compared to immunoglobulin 
G– targeted and nontargeted micelles (21). To avoid high mitogenic 
potential of full-length EGFR antibody cetuximab, we developed 
GE11 peptide (CYHWYGYTPQNVI)–decorated micelles, reported 
equal target binding capacity as of cetuximab, and showed higher 
drug accumulation and better efficacy (35). Further, small-sized 
PEGylated nanoparticles and micelles are preferentially accurate 
at the tumor and inflammatory sites via passive targeting (2).
To further improve our delivery system, here, we developed a 
new redox-sensitive therapeutic strategy to enhance the chemo-
therapeutic efficacy in pancreatic cancer, while reducing systemic 
side effects at the same time. GEM conjugated with the polymer via 
an amide bond shows very slow release from the micelles, thus 
proved to be a bottleneck for effective drug concentration. A conju-
gate with disulfide bonds, which can be easily cleaved by reducing 
GSH into sulfhydryl groups, causes the degradation of micelles and 
facilitates the release of the drug. The disulfide bond in mPEG-co-
P(Asp)-g-Ala-SS-GEM-g-DC can be readily broken by GSH, the 
concentration of which is significantly higher in tumor than the 
normal tissues. That can facilitate the precise release of GEM in 
the tumor site and limit its toxicity to normal organs.
For codelivery, we synthesized mPEG-co-P(Asp)-g-DC-g-S-S-
GEM, mPEG-P(Asp)-g-TEPA-g-DC, and GE11-PEG-P(Asp)-g-DC 
to load GEM and miR-519c in the hydrophobic core (Fig. 5). Because 
of the complexity of different components, we formulated mixed 
micelles using different ratios of these polymers. Our novel formu-
lations offer distinct advantages such as targeted delivery of GEM 
and miR-519c, prevention of rapid deamination of GEM, and the 
intratumoral release of GEM based on intracellular stimuli such as 
GSH (Fig. 5F), thus reducing toxicity to normal tissues, and enhanced 
stability of miRNA. Moreover, PEG shell can prevent aggregation 
and impart a high degree of stability and stealth effect, leading to the 
enhanced mean residence time of the drug and miRNA.
EGFR expression plays an important role in metastasis, especially 
liver metastasis, and recurrence of human pancreatic cancer (34). 
EGFR facilitates metastasis in pancreatic cancer through activation 
of Akt and extracellular signal–regulated kinase pathway. Meta-
static nodules have higher EFGR expression level than the primary 
tumor, but we did not observe those nodules in the liver, as evi-
denced by H&E staining (Fig. 6E). The total mass balance of the 
injected dose might be the reason for lower accumulation of GE11 
combination micelles in the liver than the nontarget micelles (fig. S8, 
A and B).
The rationale of combination therapy that combines two or 
more therapeutic agents is to lower the doses of individual drug 
and miRNA to achieve better therapeutic outcome and minimize 
dose-related side effects (36). Since miR-519c resensitizes pancre-
atic cancer cells to GEM, we decreased the dose of GEM from 40 to 
20 mg/kg and the dose of OMe-PS–miR-519c from 2 to 1 mg/kg 
when used in combination to determine whether there is synergism 
in their therapeutic efficacy. GEM-conjugated OMe-PS–miR-519c–
complexed mixed micelles exhibited the highest synergy in tumor 
regression after systemic administration in orthotopic pancreatic 
tumor–bearing mice (Fig. 6, B and C), with no weight loss (Fig. 6D) 
or any sign of toxicity in the vital organs of mice from any group 
during or after the treatment. We observed a significant decrease in 
HIF-1, -SMA, and Ki-67 expression and a decrease in the cleaved 
caspase-3 expressions in the combination treatment group (Fig. 6E). 
This might be attributed to GE11 peptide–decorated micelles achiev-
ing higher concentrations of GEM and OMe-PS–miR-519c in the 
tumor. High -SMA in pancreatic cancer is associated with dense 
stroma reaction and worse patient outcome. -SMA is expressed by 
activated PSCs, in response to hypoxia and Hh signaling.
Particle size distribution, shape, and surface morphology of nano-
particles affect their biodistribution and accumulation at the tumor 
site (37, 38). The particle size distribution of mPEG-co-P(Asp)-
g-TEPA-g-DC/miR-519c–complexed micelles, GEM-conjugated 
mPEG-co-P(Asp)-g-Ala-S-S-GEM-g-DC micelles, and their combi-
nation micelles was 100 ± 20 nm (Fig. 5, C and D). On the basis of 
our previous studies (2, 39), small particle size and PEGylated sur-
face prolong the blood circulation of these micelles after systemic 
administration. However, stroma acts as a barrier for nanoparticle 
delivery to the pancreatic tumor. Since miR-519c targets hypoxia 
and reduces the desmoplastic barrier, we observed a decrease in 
-SMA expression in the tumor (Fig. 6E). Therefore, there was 
significant accumulation of miR-519c and GEM in the tumor after 
systemic administration of combination micelles (Fig. 6A and fig. S8C).
The combination of GEM and miR-519c showed a synergistic 
effect in the nonmetastatic orthotopic desmoplastic pancreatic can-
cer mouse model (Fig. 6), which suggests that this treatment could 
be useful for patients with stage 0 to III pancreatic cancer. Although 
we did not observe liver metastasis during the therapeutic study, 
EGFR expression is expected to be higher in hepatic metastatic nod-
ules than in the primary tumor. Hence, GE11-based nanoparticle 
delivery platform has the potential to target the metastatic nodules in the 
liver or other distant metastasis in stage IV (34). More data related 
to the therapeutic effect study in the orthotopic pancreatic tumor mouse 
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In conclusion, the key hurdles of the clinical translation of nano-
medicine are biological barriers, large-scale manufacturing, bio-
compatibility, and safety (40, 41). The characterization of our 
combination micelles shows sufficient drug loading of GEM and 
miRNA, redox-responsive release of GEM, and controlled release of 
miRNA. The GE11-targeting mixed micelle system proposed in this 
study leads to active EGFR targeting, significant accumulation in 
desmoplastic pancreatic tumor, precise release of GEM and miR-
519c at tumor sites with the disulfide bond, and efficient synergistic 
therapeutic effect in vivo. In addition, the PEG corona prolonged 
the circulation time of micelles and has no observed toxicity in 
major organs, which enhance the biocompatibility and safety of this 
platform. Further, scale-up of this delivery system is feasible and 
can support a first-in-human phase 1 clinical trial.
MATERIALS AND METHODS
Materials
Dulbecco’s modified Eagle’s medium (DMEM) high-glucose medium, 
0.25% trypsin, and Dulbecco’s phosphate-buffered saline (DPBS) were 
purchased from HyClone (Logan, UT). Keratinocyte-SFM (serum-free 
medium) medium, bovine pituitary extract, and human recombinant 
EGF were purchased from Gibco (Chevy Chase, MD). Heat-inactivated 
FBS, antibiotic-antimycotic for cell culture, radioimmunoprecipita-
tion assay (RIPA) buffer for cell lysis and phosphatase inhibitor cock-
tail (100×), live and dead assay kit, miR-519c-3p mimics, Pierce BCA 
(bicinchoninic acid) protein assay kit, RediPlate 96 RiboGreen RNA 
quantitation kit, and FxCycle PI/RNase staining solution (F10797) 
were purchased from Thermo Fisher Scientific (Waltham, MA). 
Hepes buffer was purchased from Millipore Sigma (St. Louis, MO). 
Human c-Myc primary antibody was purchased from Proteintech 
(Manchester, UK). GLUT1, GLI1, SHH, -actin, and SMO primary 
antibodies were purchased from Santa Cruz Biotechnology (Dallas, 
TX). Laemmli buffer (4×), 10× tris/glycine/SDS protein electrophore-
sis running buffer (pH 8.3), and 10× tris-buffered saline buffer were 
purchased from Bio-Rad (Hercules, CA). HIF-1 and ABCG2 prima-
ry antibodies were purchased from Abcam (Cambridge, MA). HIF-1 
primary antibody was purchased from Novus Biologicals LLC (Cen-
tennial, CO). AGO2 primary antibody was purchased from Boster Bio 
(Pleasanton, CA). Glucose uptake cell-based assay kit (item no. 600470) 
was purchased from Cayman Chemicals (Ann Arbor, MI). RNeasy 
mini kit, miScipt II RT kit, miScript SYBR Green kit, Hs_miR-519c-3p 
miScript primer assay, and Hs_RnU6 miScript primer assay were 
purchased from QIAGEN (Germantown, MD).
Cell culture
MIA PaCa-2 cell line was purchased from the American Type 
Culture Collection (Manassas, VA), and MIA PaCa-2–resistant 
(MIA PaCa-2R) cells were generated from MIA PaCa-2 by incubat-
ing with GEM in a high-glucose DMEM supplemented with 10% 
FBS and 1% penicillin/streptomycin at 37°C, 5% CO2, and 100% 
humidity and were split when confluent. HPDE cells were cultured 
in Keratinocyte-SFM–supplemented bovine pituitary extract and 
human recombinant EGF in an identical atmosphere. hPSCs were 
cultured in stellate cell basal medium supplemented with 10% FBS, 
stellate cell growth supplement, and 1% penicillin/streptomycin. A 
hypoxic chamber filled with 94% nitrogen, 5% CO2, 1% O2, and 
100% humidity was used to generate hypoxic conditions as needed.
hPSC-conditioned medium was obtained using the following 
steps: Subconfluent PSCs were washed with PBS and incubated with 
stellate cell basal medium under above conditions for 48 hours. 
Then, the medium was collected and centrifuged for further use.
Cell migration assay
MIA PaCa-2R cells of 5 × 105 per well were seeded in six-well plate, 
and, after 24 hours, cells were treated with PBS, scrambled miRNA, 
Fig. 7. Synthesis schemes of redox-sensitive GEM-conjugated copolymer, TEPA-containing polymer for complex formation with miRNA, and EGFR-targeting 
GE11 peptide–conjugated polymer. GE11 peptide, CYHWYGYTPQNVI. (A) Synthesis of BLA-NCA. (B) Synthesis of mPEG-PBLA. (C-F) Synthesis of Ala-SS-GEM. 
(G) Synthesis of mPEG-co-P(Asp)-g-Ala-SS-GEM-g-DC and mPEG-P(Asp)-g-TEPA-g-DC. (H) Synthesis of GE11-PEG-co-P(Asp)-g-DC. rt: room temperature, EDC: 
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and miR-519c with or without PSC-conditioned medium for 6 hours 
under normoxia and hypoxia, respectively. Then, 1 × 105 cells were 
collected from each well, resuspended with 200 l of serum-free 
DMEM, and added to Transwell upper chambers. One milliliter of 
DMEM containing 20% FBS that served as the chemoattractant was 
in the lower chamber, and the cells were incubated for 24 hours 
under normoxic and hypoxic conditions. A cotton-tipped swab was 
used to remove the cells that did not migrate through the pores. 
The chambers were fixed in 4% paraformaldehyde and stained with 
crystal violet.
Glucose uptake assay and GLUT1 expression
MIA PaCa-2R cells of 5 × 104 per well were seeded in a 96-well plate. 
After 24 hours, cells were treated with miR-519c and scrambled miRNA 
in 100 l of glucose-free culture media for another 24 hours under nor-
moxic and hypoxic conditions. Glucose uptake cell-based assay kit was 
applied to evaluate glucose uptake in MIA PaCa-2R cells as following: 
2-NBDG (2-deoxy-2-((7-nitro-2,1,3-benzoxadiazol-4-yl)amino)-glucose) 
(150 g/ml) was added in glucose-free medium for 1.5 hours under nor-
moxic and hypoxic conditions. The plates were centrifuged for 5 min at 
400g at room temperature. The supernatants were discarded, and 200 l 
of the cell-based assay buffer was added to each well for washing cells 
twice. At the end, 100 l of cell-based assay buffer was added, and the 
plates were analyzed by a fluorescent reader with an excitation/emission 
of 485/535 nm to quantify 2-NBDG taken up by cells. Samples were 
normalized by the fluorescence intensity in scrambled miRNA under 
normoxia. The concentration of dCTP was quantified by LC-MS/MS.
For GLUT1 expression, MIA PaCa-2R cells at a dose of 2 × 105 
per well were seeded in a six-well plate. After 24 hours, cells were 
incubated under normoxic and hypoxic conditions. Then, cells were 
harvested, washed with cell staining buffer three times, incubated 
with GLUT1 primary antibody in cell staining buffer for 1 hour, 
followed by Cy5-conjugated secondary antibody for another 30 min, 
and analyzed by flow cytometer.
RT–quantitative PCR and Western blot
MIA PaCa-2R cells at a dose of 2 × 105 per well were plated in a 
six-well plate overnight and transfected by Lipofectamine/miR-519c 
under normoxic and hypoxic conditions for 24 hours. Then, all 
samples were subjected to total RNA isolation by QIAGEN RNeasy 
mini kit. Reverse transcription PCR was carried out using QIAGEN 
miScript II reverse transcription kit. MiR-519c and mRNA levels of 
SHH, GLI1, NME4, LDHA, HKII and TKT were quantitatively as-
sayed in Roche Light Cycler 480 using miScript SYBR Green PCR 
kit. MiR-519c and mRNA were normalized to U6 small nuclear RNA 
and glyceraldehyde-3-phosphate dehydrogenase levels, respectively. 
Primers were designed as follows: HKII-1, 5′-GAGCCACCACT-
CACCCTACT-3′ (forward) and 5′-ACCCAAAGCACACACG-
GAAGTT-3′ (reverse); TKT-1, 5′-TCCACACCATGCGCTACAAG-3′ 
(forward) and 5′-CAAGTCGGAGCTGATCTTCCT-3′ (reverse); 
NME4-1, 5′-AGGGTACAATGTCGTCCGC-3′ (forward) and 5′-GAC-
GCTGAAGTCACCCCTTAT-3′ (reverse).
For Western blot assay, all samples were isolated with RIPA 
buffer on ice within 5 min to prevent HIF-1 degradation when 
reexposed to O2, and the protein concentration was determined 
with Pierce BCA protein assay kit. After that, cell lysates were mixed 
with Laemmli loading buffer, boiled at 100°C for 5 min, loaded in 
the wells of 4 to 15% SDS–polyacrylamide gel electrophoresis gel, 
transferred by electroporation to polyvinylidene difluoride membrane, 
and incubated with blocking buffer for 1 hour at room temperature 
first and then with anti–HIF-1, anti–c-Myc, anti-ABCG2, anti–
HIF-1, and anti–-actin primary antibody overnight at 4°C. IR-680 
fluorescent dye–labeled secondary antibodies were added, followed 
by imaging in iBright FL1000. HIF-1 and -actin were both used as 
the loading control.
Cell cycle analysis
MIA PaCa-2R cells at a dose of 2 × 105 per well were plated in a six-
well plate and treated with scrambled miRNA and miR-519c under 
normoxic and hypoxic conditions for 24 hours. Then, cells were 
harvested, fixed with 70% ethanol in 4°C for 1.5 hours, and washed 
three times with PBS to remove ethanol. Subsequently, cells were 
centrifuged, a pellet of cells was collected in tubes, and 0.5 ml of 
FxCycle PI/RNase staining solution was added to each flow cytom-
etry sample for 30 min at room temperature, avoiding any exposure 
to light. Flow cytometry was used to test samples at an excitation/
emission of 532/585 nm.
Cytotoxicity, apoptosis, and efficacy in desmoplastic tumor 
spheroid model
Cytotoxicity of GEM, miR-519, and their combination was determined 
by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide) assay. MIA PaCa-2R cells were plated at a density of 5000 cells 
per well in a 96-well plate overnight. Then, GEM, miR-519c-3p, and 
the combination of GEM and miR-519c were added to 96-well plates 
with a GEM concentration ranging from 0.1 to 50 M and miR-519c 
concentration from 5 to 100 nM under hypoxic condition. After 48 hours 
of incubation, MTT solution at a concentration of 5 mg/ml was added, 
and cells were cultured for another 3 hours. The supernatant was dis-
carded, and 200 l of DMSO was added to each well. Cell viability was 
determined using a spectrophotometer.
hPSC and MIA PaCa-2R cells (1:2; a total of 600 cells in 40 l per 
well) in DMEM with 10% FBS were seeded onto Perfecta3D 96-Well 
Hanging Drop Plates (3D Biomatrix Inc., Ann Arbor MI) and incu-
bated with 5% CO2 at 37°C. On the fourth day, the spheroids were 
treated with GEM, miR-519c, and their combination. Cells treated 
with PBS and scrambled miRNA were used as controls. Morphologies 
of tumor spheroids were observed under a Zeiss microscope on 
days 6, 8, 10, and 12 to determine cytotoxicity. Live and dead assay 
kit was applied following the manufacturer’s protocol to visualize 
the apoptosis in desmoplastic tumor spheroids by confocal laser 
scanning microscopy.
AGO2 association
Targeting gene silencing by RNA interference requires RISC. AGO 
protein is a core protein binding to miRNA. We loaded AGO2 with 
miRNAs by the action of a specialized assembly RISC-loading 
complex. To assess the difference of miRNA loading between 
unmodified miR-519c and OMe-PS–miR-519c, MIA PaCa-2R cells 
at a dose of 2 × 105 per well were seeded in a six-well plate and then 
transfected with unmodified miR-519c and OMe-PS–miR-519c 
using Lipofectamine for 24 hours under normoxic and hypoxic 
conditions. Cells were washed three times with PBS and lysed using 
Pierce IP lysis buffer. A Pierce BCA assay kit was applied to quantify 
protein concentration, and all samples were diluted to 1000 g/ml 
by cell lysis buffer. Ten micrograms of AGO2 primary antibody and 
500 l of cell lysis buffer were mixed and incubated overnight at 
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of microcentrifuge tubes containing prewashed magnetic beads and 
incubated for 1 hour at room temperature. After that, beads were 
collected with a magnetic stand and washed twice with tris-buffered 
saline and ultrapure water, respectively. One hundred microliters 
of elution buffer was incubated with samples for 10 min at room 
temperature. The supernatant of miRNA-AGO2 complexes was 
harvested after separating from beads with a magnetic stand, 
following which 15 l of neutralization buffer was added. Syn-
thetic miR-39 from Caenorhabditis elegans (Cel-miR-39) was 
selected as a spike-in control for miRNA quantification by RT–
quantitative PCR. For this purpose, first, all samples were isolated 
by QIAGEN RNeasy mini kit, then reverse transcribed by miScript 
II RT kit, and amplified with miScript SYBR Green PCR kit using 
Roche LightCycler 480.
Synthesis of redox-responsive GEM-conjugated copolymer, 
TEPA-containing copolymer, and GE11 peptide–conjugated 
copolymer
Redox-responsive GEM-conjugated copolymer, TEPA-containing 
copolymer for complex formation with miRNA, and EGFR-targeting 
GE11 peptide–conjugated copolymer were synthesized, as illustrated 
in Fig. 7 as described below:
Step 1: Synthesis of BLA-NCA: We synthesized -benzyl l-aspartate 
N-carboxy anhydride (BLA-NCA) by reacting l-aspartic acid -benzyl 
ester with triphosgene in tetrahydrofuran (THF) under N2 atmosphere. 
(Fig. 7A).
Step 2: Synthesis of amphiphilic polyamino copolymer mPEG-
P(Asp): We synthesized mPEG-PBLA by ring-opening polymeriza-
tion of BLA-NCA using mPEG-NH2 (weight-average molecular 
weight, 5000) as a macroinitiator in dry N,N-dimethylformamide at 
55°C under the N2 atmosphere for 48 hours (Fig. 7B).
Step 3: Synthesis of Ala-SS-GEM: We synthesized Ala-SS-GEM 
using the following four steps: First, Boc--Ala-OH was reacted 
with bis(2-hydroxyethyl) disulfide using dicyclohexylcarbodiimide 
(DCC) coupling reaction in the presence of 4-dimethylaminopyridine 
in THF. The crude product was purified by flash column chroma-
tography to obtain the intermediate Boc-Ala-SS-OH as a colorless 
liquid (Fig. 7C). Second, Diboc-GEM was synthesized by reacting 
GEM HCl, and Boc-anhydride was dissolved in a mixture of dioxane 
and 1.0 M KOH at room temperature. After completion of the reaction, 
the reaction mixture was extracted with EtOAc (Ethyl acetate) and 
washed; dried organic layer was concentrated and, again, treated with Boc- 
anhydride in 1.0 M KOH solution. After completion of the reaction, 
the mixture was washed and dried, and the combined organic layer 
was evaporated and purified by column chromatography to give 
diboc-GEM a white solid product (Fig. 7D). Third, the intermediate 
Boc-Ala-SS-OH and diboc-GEM were reacted with triphosgene in 
the presence of pyridine in anhydrous dichloromethane (DCM) for 
1 hour at 0°C. The reaction mixture was stirred for additional 4 hours 
at room temperature. The crude product was then purified using 
column chromatography to afford Boc-Ala-SS-Diboc-GEM as a 
colorless oil (Fig. 7E). Last, Ala-SS-GEM was synthesized by remov-
ing the Boc groups in a mixture of DCM:trifluoroacetic acid (TFA) 
(1:1) (Fig. 7F).
Step 4: Ala-SS-GEM and DC (DC-NH2) were conjugated to mPEG- 
PBLA polymer by aminolysis reaction in dry dimethylformamide at 
room temperature for 48 hours to afford mPEG-co-P(Asp)-g-Ala-
SS-GEM-g-DC (Fig. 7G). The structure and molecular weight of 
mPEG-co-P(Asp)-g-Ala-SS-GEM-g-DC was determined by 1H NMR 
and gel permeation chromatography, respectively. Similarly, mPEG- 
P(Asp)-g-TEPA-g-DC was synthesized by replacing Ala-SS-GEM 
with TEPA.
Step 5: GE11 peptide (CYHWYGYTPQNVI) and DC were con-
jugated to MAL-PEG-PBLA polymer in dry dimethylformamide 
at room temperature overnight to get GE11-PEG-co-P(Asp)-g-DC 
(GE11-targeting peptide; Fig. 7H).
Preparation and characterization of micelles and drug 
release profile
The mixture of mPEG-co-P(Asp)-g-TEPA-g-DC and mPEG-co-
P(Asp)-g-Ala-SS-GEM-g-DC copolymers dissolved in acetone/
methanol (1:1, v/v) was added drop by drop to aqueous solution 
containing miR-519c. To remove residual acetone and methanol, 
samples were evaporated in a rotary evaporator. The mixture was 
filtered through polycarbonate syringe filters of 200-nm pore size. 
Particle size was measured using Malvern Zetasizer. In vitro GEM 
release from redox-responsive micelles was performed under pH 7.4 
with or without 10 mM GSH. Dialysis bags (molecular weight cut-
off, 3500 Da) were loaded with 1 ml of redox-responsive micelles, 
immersed into 30 ml of PBS buffer solutions, and shaken at a speed 
of 100 rpm at 37°C (n = 3). GEM concentration was determined by 
HPLC-UV under the following conditions: C18 column (5 m, 250 × 
4.6 mm), flow rate (1 ml/min), acetonitirle and water (90:10, v/v) as 
mobile phase, an injection volume of 20 l, and a wavelength of 
267 nm. In vitro miRNA release from TEPA micelles was carried 
out by suspending the formulation to PBS buffer solutions under 
pH 7.4 at each time point and shaking at a speed of 100 rpm at 37°C 
(n = 3). The samples were centrifuged, and the supernatants were 
collected at each time point. The concentration of released miRNA 
was tested by RiboGreen RNA quantification kit.
Biodistribution and therapeutic studies
All the animal experiments were approved by the Institutional 
Animal Care and Use Committee of the University of Nebraska 
Medical Center, Omaha, NE and carried out as per the National 
Institutes of Health guidelines. The orthotopic human pancreatic 
cancer mouse model was developed using 6- to 8-week-old male 
NSG mice (20 to 25 g). Luciferase stably expressing MIA PaCa-2R 
cells (0.5 × 106) and hPSCs (0.5 × 106) were mixed with Matrigel 
(2:1) using ice-cold instruments and syringes. Then, mice were 
anesthetized using isoflurane in an induction chamber, and 30 l 
of Matrigel cell suspension was orthotopically injected into the pan-
creas tail. Tumor growth was monitored using the Spectrum IVIS 
(PerkinElmer, Hopkinton, MA) after intraperitoneal administration 
of luciferin (20 mg/ml) (150 l per mouse). Three weeks after tumor 
injection, free GEM and OMe-PS–miR-519c, combination micelles, 
and GE11 combination micelles were injected to mice via the tail 
vein as a single administration at a dose (or dose equivalent) of 
GEM (20 mg/kg) and miR-519c (1 mg/kg). Mice were euthanized 
either at 6 or 24 hours, and major organs such as the tumor, heart, 
liver, spleen, lung, and kidney were collected for LC-MS/MS analy-
sis (4000 QTRAP, AB, Sciex Inc.). Briefly, 50 mg of tissue samples 
were homogenized in 1 ml of PBS, spiked with 5-aza-dC as the in-
ternal standard and transferred on ice immediately. Subsequently, 
3.0 ml of cold acetonitrile was added, followed by vortexing and 
high-speed centrifugation in 4°C. The supernatant was evaporated 
to dryness, and the residues were reconstituted with 200 l of aceto-
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using the Analyst software on a QTRAP 4000 mass spectrometer. 
The mass spectrometer will be operated in the positively selected 
reaction monitoring for GEM [mass/charge ratio (m/z), 264.0/112.0) 
and internal standard (m/z, 229.0/113.0). Total RNA from tissue 
samples were isolated by QIAGEN RNeasy mini kit, and RT-PCR 
assay was applied for miR-519c quantification.
For therapeutic study, mice were randomly divided into six groups 
(n = 5 per group) when the bioluminescence reached 1 × 106. GEM 
at a dose of 40 mg/kg for free GEM and GEM micelles, miR-519c at 
the dose of 2 mg/kg for miR-519c micelles, and GEM at a dose of 
20 mg/kg and miR-519c at 1 mg/kg for combination micelles were 
administered via tail vein every 3 days in a total of five injections. 
Body weights were measured before each dose administration. 
Three days after the fifth administration, the animals were eutha-
nized to harvest major organs such as the tumor, heart, liver, spleen, 
lung, and kidney. Examination included H&E staining, immuno-
histochemical, and Western blot analyses.
Statistical analysis
Results are presented as the means ± SD. One-way analysis of vari-
ance (ANOVA) was used to assess the statistical significance of dif-
ferences between groups. A cutoff of P < 0.05 was used to indicate a 
significant difference.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/46/eabd6764/DC1
View/request a protocol for this paper from Bio-protocol.
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